SELLAS Life Sciences Group, Inc.
Financials
Valuation Metrics
SELLAS Life Sciences Group, Inc.'s Market Cap is $1.73B. At end of 2025 it was $577M. Ranked #1969 of 3,116 in US market (top 63%), #738 of 1,472 on NASDAQ (top 50%), #137 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 52%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.73B | US#1,969/3,116 Sec#137/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-32M | US—/3,116 Sec—/265 |
| Total Assets | $145M | US#3,022/3,116 Sec#253/265 |
| Net Assets | $138M | US#2,752/3,116 Sec#207/265 |
| Employees | 13 | US#2,763/3,116 Sec#220/265 |
| Value | ||
| P/B | 12.54x | US#2,720/3,116 Sec#204/265 |
| FCF Yield | -1.65% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -23.58% | US#2,511/3,116 Sec#103/265 |
| ROA | -22.33% | US#2,814/3,116 Sec#135/265 |
| Financial Health | ||
| Debt Ratio | 5.61% | US#44/3,116 Sec#18/265 |
| Total Debt | $737000.00 | US#2,974/3,116 Sec#244/265 |
| FCF | $-28M | US#2,459/3,116 Sec#101/265 |
| Cash | $138M | US#1,996/3,116 Sec#139/265 |
| Current Ratio | 18.83x | US#121/3,116 Sec#28/265 |
| Performance | ||
| 1Y Return | 369.51% | US#12/3,116 Sec#5/265 |
| 1M Return | -27.21% | US#2,649/3,116 Sec#201/265 |
| From 52W High | -46.19% | US#2,253/3,116 Sec#158/265 |
| 1Y MDD | -44.73% | US#1,671/3,116 Sec#93/265 |
| Trading | ||
| Volume | 14,057,445 shares | US#220/3,116 Sec#14/265 |
| Trading Value | $125M | US#965/3,116 Sec#59/265 |
| Per Share | ||
| EPS | $-0.16 | US—/3,116 Sec—/265 |
| BPS | $0.68 | US#2,729/3,116 Sec#211/265 |
Company Info
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.